# Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

> **NCT05019534** · PHASE1 · UNKNOWN · sponsor: **West China Hospital** · enrollment: 12 (estimated)

## Conditions studied

- BRAF V600E-mutated /MSS Metastatic Colorectal Cancer
- Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody

## Interventions

- **DRUG:** Vemurafenib Oral Tablet [Zelboraf]
- **DRUG:** Cetuximab Injection [Erbitux]
- **DRUG:** Camrelizumab

## Key facts

- **NCT ID:** NCT05019534
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-15
- **Primary completion:** 2022-08-01
- **Final completion:** 2022-12-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2022-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05019534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05019534, "Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05019534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*